Eric is an investor at Mubadala Capital based in the San Francisco office. His training is in therapeutics discovery and preclinical development and early-stage business development and licensing. Previously, Eric was Vice President of Asset Acquisition at BridgeBio Pharma responsible for company creation and operations across multiple therapeutic areas. At BridgeBio he led the creation and early operations of four start-ups, two based on licensing clinical stage assets, and the other two based on spinning out discovery-stage technology from academia. His time in industry also includes project management overseeing IND-enabling studies and start-up fundraising. He received his PhD in biological engineering from Rice University and his undergraduate degree in biological engineering from MIT.